Intravaginal zinc oxide tetrapod nanoparticles as novel immunoprotective agents against genital herpes

Journal of Immunology

Volumn 196, Issue 11, 2016, Pages 4566-4575

  Antoine, Thessicar E ^a   Hadigal, Satvik R ^a   Yakoub, Abraam M ^a   Mishra, Yogendra Kumar ^b   Bhattacharya, Palash ^a   Haddad, Christine ^a   Valyi Nagy, Tibor ^a   Adelung, Rainer ^b   Prabhakar, Bellur S ^a   Shukla, Deepak ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; MEDROXYPROGESTERONE ACETATE; MICROBICIDE; OXYGEN; UNCLASSIFIED DRUG; ZINC OXIDE NANOPARTICLE; ZINC OXIDE TETRAPOD NANOPARTICLE; NANOPARTICLE; ZINC OXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEMALE GENITAL TRACT INFECTION; GENITAL HERPES; GENITAL TRACT INFECTION; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MORTALITY; MOUSE; NANOENGINEERING; NONHUMAN; PRIORITY JOURNAL; REINFECTION; VAGINITIS; VIRION; ANIMAL; CELL CULTURE; CHEMISTRY; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; HELA CELL LINE; HERPES GENITALIS; IMMUNOLOGY; MICROBIAL SENSITIVITY TEST; PARTICLE SIZE; PATHOLOGY; STRUCTURE ACTIVITY RELATION; VERO CELL LINE;

ANIMALS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; FEMALE; HELA CELLS; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; PARTICLE SIZE; STRUCTURE-ACTIVITY RELATIONSHIP; VERO CELLS; ZINC OXIDE;

EID: 84975150208     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502373     Document Type: Article

References (38)

1. Whitley, R. J., and B. Roizman. 2001. Herpes simplex virus infections. Lancet 357: 1513-1518.
2. Shukla, D., and P. G. Spear. 2001. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J. Clin. Invest. 108: 503-510.
3. Andrei, G., and R. Snoeck. 2013. Herpes simplex virus drug-resistance: new mutations and insights. Curr. Opin. Infect. Dis. 26: 551-560.
4. Sanvicens, N., and M. P. Marco. 2008. Multifunctional nanoparticles-properties and prospects for their use in human medicine. Trends Biotechnol. 26: 425-433.
5. Davis, M. E., Z. G. Chen, and D. M. Shin. 2008. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7: 771-782.
6. Hrkach, J., D. Von Hoff, M. Mukkaram Ali, E. Andrianova, J. Auer, T. Campbell, D. De Witt, M. Figa, M. Figueiredo, A. Horhota, et al. 2012. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4: 128ra39.
7. Antoine, T. E., Y. K. Mishra, J. Trigilio, V. Tiwari, R. Adelung, and D. Shukla. 2012. Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection. Antiviral Res. 96: 363-375.
8. Coleman, J. L., and D. Shukla. 2013. Recent advances in vaccine development for herpes simplex virus types I and II. Hum. Vaccin. Immunother. 9: 729-735.
9. Koelle, D. M., J. M. Frank, M. L. Johnson, and W. W. Kwok. 1998. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J. Virol. 72: 7476-7483.
10. Docherty, J. J., M. M. Fu, J. M. Hah, T. J. Sweet, S. A. Faith, and T. Booth. 2005. Effect of resveratrol on herpes simplex virus vaginal infection in the mouse. Antiviral Res. 67: 155-162.
11. Park, P. J., T. E. Antoine, A. V. Farooq, T. Valyi-Nagy, and D. Shukla. 2013. An investigative peptide-acyclovir combination to control herpes simplex virus type 1 ocular infection. Invest. Ophthalmol. Vis. Sci. 54: 6373-6381.
12. Peng T., M. Ponce-de-Leon, H. Jiang, G. Dubin, J. M. Lubinski, R. J. Eisenberg, and G. H. Cohen. 1998. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge. J. Virol. 72: 65-72.
13. Iwanaga, H., M. Fujii, and S. Takeeuchi. 1993. Growth model of tetrapod zinc oxide particles. J. Cryst. Growth 134: 275-280.
14. Mishra, Y. K., G. Modi, V. Cretu, V. Postica, O. Lupan, T. Reimer, I. Paulowicz, V. Hrkac, W. Benecke, L. Kienle, and R. Adelung. 2015. Direct growth of freestanding ZnO tetrapod networks for multifunctional applications in photocatalysis, UV photodetection, and gas sensing. ACS Appl. Mater. Interfaces 7: 14303-14316.
15. Ferlazzo, G., D. Thomas, S. L. Lin, K. Goodman, B. Morandi, W. A. Muller, A. Moretta, and C. Munz. 2004. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J. Immunol. 172: 1455-1462.
16. Lee-MacAry, A. E., E. L. Ross, D. Davies, R. Laylor, J. Honeychurch, M. J. Glennie, D. Snary, and R. W. Wilkinson. 2001. Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide. J. Immunol. Methods 252: 83-92.
17. Leenen, P. J., K. Radosević, J. S. Voerman, B. Salomon, N. van Rooijen, D. Klatzmann, and W. van Ewijk. 1998. Heterogeneity of mouse spleen dendritic cells: in vivo phagocytic activity, expression of macrophage markers, and subpopulation turnover. J. Immunol. 160: 2166-2173.
18. Adelung, R., S. Kaps, Y. K. Mishra, M. Claus, T. Presusse, and C. Wolpert, inventors. Elastic material with a pore space bridge at the particle level by nanobridges between particles. German Patent DE 10 2010 012 385.4, European Application EP11 724360.0. 2011 Mar 11.
19. Mishra, Y. K., S. Kaps, A. Schuchardt, I. Paulowicz, X. Jin, D. Gedamu, S. Freitag, M. Claus, S. Wille, A. Kovalev, et al. 2013. Fabrication of macroscopically flexible and highly porous 3D semiconductor networks from interpenertrating nanostructiures by a simple flame transport approach. Part. Part. Syst. Charact. 30: 775-783.
20. Parr, M. B., L. Kepple, M. R. McDermott, M. D. Drew, J. J. Bozzola, and E. L. Parr. 1994. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab. Invest. 70: 369-380.
21. Taylor, J. M., E. Lin, N. Susmarski, M. Yoon, A. Zago, C. F. Ware, K. Pfeffer, J. Miyoshi, Y. Takai, and P. G. Spear. 2007. Alternative entry receptors for herpes simplex virus and their roles in disease. Cell Host Microbe 2: 19-28.
22. Koelle, D. M., and L. Corey. 2008. Herpes simplex: insights on pathogenesis and possible vaccines. Annu. Rev. Med. 59: 381-395.
23. Koelle, D. M., H. B. Chen, M. A. Gavin, A. Wald, W. W. Kwok, and L. Corey. 2001. CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J. Immunol. 166: 4049-4058.
24. + T cells can clear established lytic infections from skin and nerves and can partially limit the early spread of virus after cutaneous inoculation. J. Immunol. 172: 392-397.
25. + T cells into the nervous system following ocular herpes simplex virus-1 infection. J. Immunol. 174: 2919-2925.
26. Chentoufi, A. A., and L. Benmohamed. 2012. Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections. Clin. Dev. Immunol. 2012: 149135.
27. Metzger, B., J. Podlech, S. Muller, and D. Falke. 1988. Suppression of humoral immune response against herpes simplex virus induced by defective strains, tsand TK-mutants. Arch. Virol. 99: 143-152.
28. Gupta, R., T. Warren, and A. Wald. 2007. Genital herpes. Lancet 370: 2127-2137.
29. Awasthi, S., and H. M. Friedman. 2013. Status of prophylactic and therapeutic genital herpes vaccines. Curr. Opin. Infect. Dis. 6: 6-12.
30. Mertz, G. J., R. Ashley, R. L. Burke, J. Benedetti, C. Critchlow, C. C. Jones, and L. Corey. 1990. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J. Infect. Dis. 161: 653-660.
31. Corey, L., A. G. Langenberg, R. Ashley, R. E. Sekulovich, A. E. Izu, J. M. Douglas, Jr., H. H. Handsfield, T. Warren, L. Marr, S. Tyring, et al; Chiron HSV Vaccine Study Group. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 282: 331-340.
32. Kohl, S., E. D. Charlebois, M. Sigouroudinia, C. Goldbeck, K. Hartog, R. E. Sekulovich, A. G. Langenberg, and R. L. Burke. 2000. Limited antibodydependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. J. Infect. Dis. 181: 335-339.
33. Bernstein, D. I., F. Y. Aoki, S. K. Tyring, L. R. Stanberry, C. St-Pierre, S. D. Shafran, G. Leroux-Roels, K. Van Herck, A. Bollaerts, and G. Dubin, GlaxoSmithKline Herpes Vaccine Study Group. 2005. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin. Infect. Dis. 40: 1271-1281.
34. Belshe, R. B., P. A. Leone, D. I. Bernstein, A. Wald, M. J. Levin, J. T. Stapleton, I. Gorfinkel, R. L. Morrow, M. G. Ewell, A. Stokes-Riner, et al; Herpevac Trial for Women. 2012. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 366: 34-43.
35. Petro, C., P. A. González, N. Cheshenko, T. Jandl, N. Khajoueinejad, A. Bénard, M. Sengupta, B. C. Herold, and W. R. Jacobs. 2015. Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. eLife 4: 4.
36. McKee, A. S., M. W. Munks, M. K. MacLeod, C. J. Fleenor, N. Van Rooijen, J. W. Kappler, and P. Marrack. 2009. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J. Immunol. 183: 4403-4414.
37. Nohynek, G. J., E. K. Dufour, and M. S. Roberts. 2008. Nanotechnology, cosmetics and the skin: is there a health risk? Skin Pharmacol. Physiol. 21: 136-149.
38. +)-T cell-epitopes-based immunotherapeutic vaccine candidates? Vaccine 29: 5824-5836.